Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

Conditions

Sleep Apnea, Obstructive

Keywords

Liraglutide, Continuous positive airway pressure, Insulin resistance, Vascular inflammation

Brief summary

This is an explorative, proof-of-concept study exploring the potential therapeutic role of a Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on metabolic parameters, blood pressure, endothelial function, coronary artery calcification, vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to severe obstructive sleep apnea

Cliona O’Donnell, Ailbhe King, Guillaume Vial, Emily O’Neill, Shane Crilly et al. (12 authors)

Journal of Sleep Research2025-07-281 citations

10.1111/jsr.70152

Continuous Positive Airway Pressure But Not GLP1-Mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study

Cliona O’Donnell, Shane Crilly, Anne O’Mahony, Brian O’Riordan, Mark Traynor et al. (12 authors)

Annals of the American Thoracic Society2023-12-1444 citations

10.1513/annalsats.202309-821oc

The effect of CPAP therapy on coronary artery plaque volume in obstructive sleep apnoea: data from a proof-of-concept study

Cliona O’Donnell, Shane Crilly, Anne O’Mahony, Brian O’Riordan, Racheal Gitau et al. (9 authors)

2023-09-09

10.1183/13993003.congress-2023.oa3287

Liraglutide-Based Weight Loss versus CPAP Therapy in improving Sleep Quality and Quality of Life of Patients with Obstructive Sleep Apnoea - an Explorative, Proof of Concept Study

Cliona O’Donnell, Anne O’Mahony, Mark Traynor, Rachael Gitau, Stephen J. Ryan

2023-04-203 citations

10.1183/23120541.sleepandbreathing-2023.110

The effect of CPAP therapy on aortic inflammation in obstructive sleep apnoea: data from a proof-of-concept PET-CT study

Colm P. O’Donnell, S Crilly, Alexander T. O'Mahony, J Dodd, D O'Shea et al. (7 authors)

04.02 - Clinical and epidemiological respiratory sleep medicine2022-09-04

10.1183/13993003.congress-2022.2126

Interventions

DRUGLiraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml

GLP-1 analogue treatment in combination with advice on diet and physical exercise

DEVICEContinuous positive airway pressure treatment

Gold standard treatment for obstructive sleep apnea

COMBINATION_PRODUCTLiraglutide and CPAP

Combination of both treatments

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

No

Inclusion criteria

* Newly diagnosed moderate-severe OSA (by standard PSG) * Body mass index between 30 - 40 * Age 18 - 60 years * Able to provide written, informed consent

Exclusion criteria

* Pregnancy * Requirement for supplemental oxygen * Previous diagnosis of OSA or previous CPAP treatment * Diagnosis of Diabetes * Previous treatment with GLP-1 analogue * Previous surgical treatment for obesity * Active treatment for malignancy or severe psychiatric disorder * Acute coronary syndrome or stroke within 3 months prior to study * History of decompensated heart failure * Professional drivers or drivers with a history of road-traffic accident due to sleepiness * Severe excessive daytime sleepiness defined as Epworth sleepiness scale \>15

Design outcomes

Primary

Measure	Time frame	Description
Insulin resistance	6 months	Improvement in insulin resistance defined by HOMA-IR

Secondary

Measure	Time frame	Description
Glucose tolerance	6 months	Change in glucose tolerance measured by oral glucose tolerance test
OSA Severity	6 months	Change in apnea/hypopnea index as per polysomnography
Blood pressure	6 months	Change in 24-hour blood pressure
Weight	6 months	Change in body mass index
Coronary artery calcification	6 months	Change in coronary artery calcification score determined by Coronary artery CT
Vascular inflammation	6 months	Change in vascular inflammation determined via FDG-PET scan
Endothelial function	6 months	Change in microvascular endothelial function measured by EndoPat

Countries

Ireland

Outcome results

None listed